Showing results filtered by:
601 Results
We study how Salmonella Typhimurium interacts with mammalian host cells and the roles these interactions play in pathogenesis.
Last Reviewed: September 28, 2022
Information for researchers on how to create a budget when applying for a grant from NIAID.
Last Reviewed: August 11, 2016
On this 35 th World AIDS Day, the National Institutes of Health (NIH) joins its partners in honoring the lives lost due to the HIV pandemic. For decades, this virus has exacted a tragic toll, affecting people, families, and communities worldwide, threatening social and economic development, and exacerbating stigma, often toward people who already experience discrimination and health disparities
Published: December 1, 2023
Raphaela T. Goldbach-Mansky, M.D., M.H.S., is the Chief of the Translational Autoinflammatory Diseases Section. Dr. Goldbach-Mansky's translational autoinflammatory research program focuses on clinical and translational studies in children with early-onset autoinflammatory diseases.
Last Reviewed: April 26, 2024
Information for NIAID grantees about compliance with all policies that affect international grants.
Last Reviewed: September 25, 2019
The research group investigates the replication of poxviruses, viral immune defense proteins and recombinant vaccines against other viral pathogens including monkeypox virus, coronaviruses, and immunodeficiency viruses.
Last Reviewed: September 23, 2022
The Mosquito Immunity and Vector Competence Section investigates the interactions between the mosquito immune system and Plasmodium parasites to understand how they affect malaria transmission.
Last Reviewed: September 23, 2022
Here NIH covers factors to consider for revising and resubmitting an application, rules for resubmitting, and our advice for resubmission applications.
Last Reviewed: September 23, 2024
Resources for NIAID grantees about the first events that occur after applications go through peer review and are approved for funding.
Last Reviewed: December 18, 2019
Patrick E. Duffy, M.D., is Chief of the Laboratory of Malaria Immunology and Vaccinology, the Vaccine Development Unit, and the Pathogenesis and Immunity Section. The Pathogenesis and Immunity Section conducts human and animal studies of malaria pathogenesis and host immunity, including population-based studies in communities exposed to Plasmodium falciparum. Our research emphasizes pregnant women and children, the populations most susceptible to malaria morbidity and mortality, with collaborative cohort studies ongoing in Mali, Liberia and Guinea.
Last Reviewed: March 11, 2025
Role of vector saliva in blood feeding by arthropods, in particular determining the structure-function relationships of their components.
Last Reviewed: September 27, 2022
The Vector Molecular Biology Section focuses on understanding how molecules from arthropod vectors are critical for the success of pathogen transmission and translating this knowledge into disease control opportunities.
Last Reviewed: September 27, 2022
Michail Lionakis, M.D., Sc.D., is Chief of the Laboratory of Clinical Immunology and Microbiology and the Chief of the Fungal Pathogenesis Section. The section's research focuses on 1) cellular and molecular factors that regulate the immune response against mucosal and invasive candidiasis and invasive aspergillosis in clinically relevant animal models and 2) better understanding the genetic and immune defects that underlie enhanced susceptibility to mucocutaneous and invasive fungal infections in humans.
Last Reviewed: February 18, 2025
Information for researchers about which changes can be made to grants independently and which require NIAID permission.
Last Reviewed: September 29, 2023
TBRS is a multidisciplinary group composed of chemists, microbiologists, veterinarians, imaging scientists, and clinicians with a shared objective of improving chemotherapy for tuberculosis (TB) patients. Projects span chemical biology, medicinal chemistry, host-pathogen interactions, animal models of experimental chemotherapy, and experimental medicine clinical studies in TB patients.
Last Reviewed: March 11, 2025
The 205 th meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened at 5601 Fishers Lane in the Grand Hall at 10:30 a.m. on Monday, September 11, 2023. Dr. Hugh Auchincloss, Acting Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public
Last Reviewed: January 11, 2024
An overview of the NIAID Research Education Program (R25) and the Stimulating Access to Research in Residency (StARR) Program (R38).
Last Reviewed: April 8, 2025
The Pathogenesis and Immunity Section conducts human and animal studies of malaria pathogenesis and host immunity, including population-based studies in communities exposed to Plasmodium falciparum. Our research emphasizes pregnant women and children, the populations most susceptible to malaria morbidity and mortality, with collaborative cohort studies ongoing in Mali, Liberia and Guinea.
Last Reviewed: October 3, 2022
BMSBS studies the structural and molecular details of cellular recognition in immune response. We focus on cell surface molecules (MHC I and II, T cell receptors, NK cell receptors) using genetic, biochemical, biophysical tools including X-ray and cryo-EM to understand how crucial components interact. We study viral immunoevasins and how viral structures are recognized by antibodies.
Last Reviewed: September 26, 2022
We offer the following guidance when considering or preparing NIAID multiproject research applications. For P01, also check our P01 Program Project Grants guide. Table of Contents Contact NIAID Early If You’re Considering a Multiproject Application Features of Multiproject Grants Your Options for Opportunity Type May You Submit a Multiple PI Application? Contact NIAID and Obtain Preapproval Option
Last Reviewed: September 14, 2022
The 206 th meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Tuesday, January 30, 2024. Dr. Jeanne Marrazzo, Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:45 a.m. and from 1
Last Reviewed: May 21, 2024
Innovative Drug Delivery for Spinal Cord Injury: NurExone's Exosome-Based siRNA Therapy with FDA Endorsement and Expanding Pipeline for Neuronal Regeneration November 14, 2024 Presenter: Dr. Lior Shaltiel, CEO, NurExone Biologic Inc. NurExone is leading the advancement of drug delivery systems for CNS indications and specially in spinal cord injury treatment. Their cutting-edge exosome-based siRNA
Last Reviewed: November 13, 2024
Opportunistic fungal infections represent major causes of morbidity and mortality despite the administration of antifungal therapy. A better mechanistic understanding of host-fungal interactions will inform the development of improved immune-based strategies for the prevention, risk stratification, prognostication, vaccination, and treatment of vulnerable patient populations. In the Fungal
Last Reviewed: February 18, 2025
This page explains how principal investigators using live vertebrate animals should adhere to NIH requirements, prepare applications, and manage grants.
Last Reviewed: November 21, 2024
The 207 th meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Monday, June 3, 2024. Dr. Jeanne Marrazzo, Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:45 a.m. and from 1:00 p
Last Reviewed: August 21, 2024